Archive Newsletter

1. 01.30.26 -- Reclaiming Control From Your Raw Materials 1/30/2026
   01/30/26 Cell & Gene Newsletter
2. 01.29.26 -- Advancing Off-The-Shelf CRISPR CAR-T Therapies With Rachel Haurwitz 1/29/2026
   01/29/26 Cell & Gene Newsletter
3. 01.28.26 -- Single-Use Standards Are Maturing, But The Process Remains King 1/28/2026
   01/28/26 Cell & Gene Newsletter
4. 01.27.26 -- STREAM Edition: Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz 1/27/2026

   01/27/26 Cell & Gene Newsletter

5. 01.27.26 -- The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/27/2026
   01/27/26 Cell & Gene Newsletter
6. 01.26.26 -- Deploying A Vendor Life Cycle Oversight Model 1/26/2026
   01/26/26 Cell & Gene Newsletter
7. 01.23.26 -- Why The EU Biotech Act Matters To The U.S.: A Clinical Perspective 1/23/2026
   01/23/26 Cell & Gene Newsletter
8. 01.22.26 -- Support Participants, Sites & Communities With The Right Research Models 1/22/2026

   01/22/26 Cell & Gene Newsletter

9. 01.22.26 -- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26 1/22/2026
   01/22/26 Cell & Gene Newsletter
10. 01.21.26 -- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026 1/21/2026
    01/21/26 Cell & Gene Newsletter